Capsule ( Specialty Retail) key facts
- Operator of digital pharmacy services intended to facilitate the delivery of prescription medication.
- It has raised $690.0M across 1 recorded rounds; the latest was Later Stage VC ($100.0M) in Dec 2022.
- Notable investors include Global Founders Capital, Flybridge (New York), TriplePoint Capital, MicroVentures, Thrive Capital — 34 tracked in total.
- Status: Privately Held (backing).
Who backs Capsule ( Specialty Retail)
34+Membership and data by Private Market View
- ·The complete investor list: 34 names
- ·Watch Capsule ( Specialty Retail): the Monday email on marks, rounds and moves
Capsule ( Specialty Retail) funding rounds
1 roundsHow much has Capsule ( Specialty Retail) raised?
Capsule ( Specialty Retail) has raised $690 million in total; 1 of its rounds is on record. The largest on record was a $100 million later-stage round in Dec 2022.
Capsule ( Specialty Retail) investors
34 investors are on record for Capsule ( Specialty Retail), including Global Founders Capital, Flybridge (New York), TriplePoint Capital and MicroVentures. By type, the record holds 14 venture capital firms, 3 family offices and 3 growth equity firms. The later-stage round in Dec 2022 drew 2 investors.
About Capsule ( Specialty Retail)
Operator of digital pharmacy services intended to facilitate the delivery of prescription medication. The company's platform accepts prescriptions from doctors and allows patients to switch refills from the old pharmacy to the platform, enabling patients to get medication delivered on the same day.
- Industry
- Specialty Retail
- Sector
- Consumer Products and Services (B2C)
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 823
- Website
- capsule.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Capsule ( Specialty Retail) doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.